Nazih Zuhdi Transplant Institute, INTEGRIS Baptist Medical Center, 3300 NW Expressway, Oklahoma City, OK 73112, USA.
Crit Rev Oncol Hematol. 2012 May;82(2):116-40. doi: 10.1016/j.critrevonc.2011.05.005. Epub 2011 Jun 15.
With increased understanding of cancer biology, a multitude of pathological, genetic, and molecular events that drive hepatocarcinogenesis, including angiogenesis, invasion, and metastasis, has been identified. Lately, they are being aggressively evaluated due to challenges involved in establishing early diagnosis, optimizing therapy for cancer inducing hepatotrophic viruses, minimizing the emergence of new tumors, and preventing recurrence after surgical resection or liver transplantation. This comprehensive review examines and critiques the evidence from published manuscripts reporting various tissue and serum biomarkers involved in hepatocellular carcinoma. These markers not only help in prediction of prognosis or recurrence, but may also assist in deciding appropriate modality of therapy and represent novel targets for potential therapeutic agents.
随着对癌症生物学的深入了解，已经确定了多种驱动肝癌发生的病理、遗传和分子事件，包括血管生成、侵袭和转移。最近，由于在建立早期诊断、优化致癌性嗜肝病毒的治疗、最小化新肿瘤的出现以及预防手术切除或肝移植后的复发方面存在挑战，这些事件受到了积极评估。本综述检查和评论了发表的报告各种组织和血清生物标志物在肝细胞癌中的作用的文献证据。这些标志物不仅有助于预测预后或复发，而且还可能有助于决定适当的治疗方式，并代表潜在治疗剂的新靶点。
